Economic information and modeling reportBudget impact model
Approach and framework
2 evidence topics · 5 sources
Budget impact model of ficerafusp alfa: approach and framework
No evidence found.
Good-practice framework for budget impact analysis
“The key elements of a BIA include estimating the size of the eligible population, the current mix of treatments and the expected mix after the introduction of the new intervention, the cost of the treatment mixes, and any changes expected in condition-related costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Where possible, the BIA calculations should be performed by using a simple cost calculator approach because of its ease of use for budget holders.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In instances, however, in which the changes in eligible population size, disease severity mix, or treatment patterns cannot be credibly captured by using the cost calculator approach, a cohort or patient-level condition-specific model may be used to estimate the budget impact of the new intervention, accounting appropriately for those entering and leaving the eligible population over time.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, the Task Force recommends that the analyst use the simplest design that will generate credible and transparent estimates.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The model should be consistent with that used for the CEA with regard to clinical and economic assumptions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Model structures used in economic evaluations of first-line regimens for recurrent or metastatic disease
“A three-state partitioned-survival model was used to project costs and outcomes over 20 years with 3% annual discounting.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Time-on-treatment was derived from KEYNOTE-048 or approximated using network meta-analysis progression-free survival estimates.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A Markov structure was conducted to evaluate the cost and effectiveness of pembrolizumab monotherapy or pembrolizumab plus chemotherapy vs. cetuximab plus chemotherapy in the first-line treatment of recurrent or metastatic HNSCC from the United States payer's perspective.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote